Skip to content

The relationships between hyperandrogenism and caridiovascular risk in PCOS patients

Establishment of cardiovascular risk stratification system based on different types of hyperandrogenemia in PCOS patientsts

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065692
Enrollment
Unknown
Registered
2022-11-11
Start date
2022-11-07
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome

Interventions

PCOS patients with hyperandrogenism:No
Non PCOS patients:No

Sponsors

Chongqing health center for women and children
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of PCOS was according to the 2003 Rotterdam criteria; 2. 18-60 years old; 3. Did not receive hormone therapy or hypoglycemic drugs within 3 months before the enrollment; 4. Received the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with Cushing's syndrome, congenital adrenal hyperplasia, androgen-secreting tumors, 21-hydroxylase-deficient non-classic adrenal hyperplasia, thyroid dysfunction, hyperprolactinemia or other causes of anovulation or hyperandrogenism were excluded; 2. Pregnant or lactating women are excluded; 3. Received hormone therapy or hypoglycemic drugs within 3 months before the enrollment; 4. Patients with amenorrhea who had follicles larger than 9mm in diameter or a serum estrogen level >= 80pg/ml were considered to have ovulation and were excluded.

Design outcomes

Primary

MeasureTime frame
Serum T, A2, DHT, DHEAS, DHT, SHBG,free-T;

Countries

China

Contacts

Public ContactHao Lijuan

Chongqing health center for women and children

haolj2002@163.com+86 13002357880

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026